Australians living with MPN step closer to accessing Pegasys treatment
Thursday, 08 June 2017
The drug interferon alfa-2a (Pegasys®) was finally listed on the agenda of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting on March 8 and many Australians are awaiting the results of the discussion.
For Nathalie Cook, who was diagnosed with MPN in 2008, this achievement was especially exciting
Life-saving Hodgkin lymphoma treatment now available on PBS
Sunday, 02 April 2017
Participants of two Leukaemia Foundation surveys have helped inform the Pharmaceutical Benefits Advisory Committee of the benefits of brentuximab vedotin, a potentially life-saving treatment for Australians diagnosed with a form of Hodgkin lymphoma*, supporting its listing on the PBS from April 1.
The PBS listing of brentuximab
Getting patients faster access to clinical trials and effective treatments
Sunday, 29 January 2018
We are pleased to announce the recent appointment of Caroline Turnour as the Leukaemia Foundation’s General Manager of Research, Advocacy and Services.
A member of our national management team, Caroline will be a strong and influential advocate for the rights of all people and families affected by
Ageing population increasing Queensland’s blood cancer burden
Tuesday , 17 January 2017
Blood cancer death rates in Queensland have soared by a third in just 10 years, a further symptom of the country’s ageing population, according to a new analysis.
The Leukaemia Foundation’s investigation shows the number of Australians dying from blood cancer is now DOUBLE those losing
Breakthrough cancer drug venetoclax approved for use in Australia
Tuesday, 10 January 2017
New anti-cancer drug, venetoclax which has the power to ‘melt away’ advanced forms of chronic lymphocytic leukaemia (CLL) was recently granted approval by the Australian Therapeutic Goods Administration (TGA).
The drug will be marketed as VenclextaTM and is approved for Australians with relapsed or refractory CLL with 17p
Holden donates 17 Commodores to help Australians get to life-saving treatment
Sunday, 29 October 2016
Finding a way to attend vital appointments can be an added burden to someone already facing a life-threatening blood cancer diagnosis.
Holden are helping to alleviate this stress and provide better journeys to treatment by supplying the Leukaemia Foundation’s nationwide Patient Transport Program with 17 new Commodores.
Streamlined approvals to improve access to lifesaving medicines
Tuesday, 25 October 2016
The Leukaemia Foundation welcomes the Australian Government’s commitment to new reforms to improve the way medicines are accessed for use in Australia.
By helping to streamline access to medicines and medical devices including access to novel and life-saving therapies, the reforms aim to strike a balance by
Building of Hope opens
Friday, 30 September 2016
The Leukaemia Foundation was thrilled to officially open the doors to the Building of Hope, the new Victorian Patient Accommodation Centre on Wednesday July 13.
The occasion was marked by an official ribbon cutting ceremony, attended by the Minister for Health, Hon Jill Hennessy. Minister Hennessy was given
Towards better treatment outcomes in lymphoma by personalising medicine
Thursday, 01 September 2016
New directions in treatment for lymphoma are increasingly based on ‘personalised medicine’, which means identifying the best treatment for an individual patient.
The Leukaemia Foundation’s Head of Blood Cancer Support, Anthony Steele, said the overall aim of this approach was to optimise treatment outcomes.
“Currently, we do not
Targeted therapies offer fresh hope for AML
Friday, 22 July 2016
The results of a clinical trial involving a new combination therapy of Venetoclax and chemotherapy are providing hope for Australians diagnosed with AML
Clinical and translational AML researcher, Dr Andrew Wei and his teams at the Alfred Hospital and Monash University, are optimistic about the combination therapy,